Dimitry Nuyten
Chief Tech/Sci/R&D Officer at ARCUS BIOSCIENCES, INC.
Net worth: 2 M $ as of 2024-03-30
Profile
Dimitry S.
A.
Nuyten is currently the Chief Medical Officer at Arcus Biosciences, Inc. He previously worked as the Group Medical Director at Bristol Myers Squibb Co. from 2008 to 2013, and as the Vice President at Pfizer Inc. from 2013 to 2019.
In 2021, he was the Chief Medical Officer & Senior Vice President at Nektar Therapeutics.
He also served as the Chief Medical Officer at Aduro BioTech, Inc. Dr. Nuyten holds a doctorate degree from both the University of Amsterdam and the University of Groningen.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC.
0.11% | 2024-01-22 | 99,195 ( 0.11% ) | 2 M $ | 2024-03-30 |
Dimitry Nuyten active positions
| Companies | Position | Start |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2022-07-31 |
Former positions of Dimitry Nuyten
| Companies | Position | End |
|---|---|---|
| NEKTAR THERAPEUTICS | Chief Tech/Sci/R&D Officer | 2022-03-31 |
| PFIZER, INC. | Corporate Officer/Principal | 2019-02-28 |
| BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | 2013-05-31 |
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Dimitry Nuyten
| University of Amsterdam | Doctorate Degree |
| University of Groningen | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PFIZER, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Dimitry Nuyten
